Is HLA-DR4 or the HLA-DRB1*0402 allele associated with decreased risk for CML? [7]

Leukemia

Volumn 15, Issue 1, 2001, Pages 192-193

  Pawelec, G ^a   Wagner, W ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN; HLA DR1 ANTIGEN; HLA DR4 ANTIGEN; HYBRID PROTEIN; PEPTIDE;

ALLELE; ANTIGEN FUNCTION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ASSAY; BINDING AFFINITY; CANCER RESISTANCE; CANCER RISK; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HETEROZYGOTE; HLA TYPING; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; SENSITIZATION; T LYMPHOCYTE;

EID: 0035144353     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401946     Document Type: Letter

References (6)

1. HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry
2. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors
3. Characterisation of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain associated αβ dimers
4. The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide
5. + T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates
6. Recognition of peptides corresponding to the joining region of p210 BCR-ABL protein by human T cells